FDA converts brexu-cel (Tecartus) to standard approval

FDA converted the CAR-T cell therapy brexu-cel (Tecartus) from accelerated to standard approval for relapsed and refractory mantle-cell lymphoma, backed by ZUMA-2 long-term follow-up.